These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20047914)

  • 1. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
    Pachón-Ibáñez ME; Docobo-Pérez F; López-Rojas R; Domínguez-Herrera J; Jiménez-Mejias ME; García-Curiel A; Pichardo C; Jiménez L; Pachón J
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1165-72. PubMed ID: 20047914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains.
    Pachón-Ibáñez ME; Docobo-Pérez F; Jiménez-Mejias ME; Ibáñez-Martínez J; García-Curiel A; Pichardo C; Pachón J
    Eur J Clin Microbiol Infect Dis; 2011 Jul; 30(7):895-901. PubMed ID: 21336548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME; Fernández-Cuenca F; Docobo-Pérez F; Pachón J; Pascual A
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Ardanuy C; Gudiol F
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1946-52. PubMed ID: 12019113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G; Demiraslan H; Elmali F; Ahmed SS; Metan G; Alp E; Doganay M
    Chemotherapy; 2013; 59(5):325-9. PubMed ID: 24525528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.
    Dong X; Chen F; Zhang Y; Liu H; Liu Y; Ma L
    J Antibiot (Tokyo); 2014 Sep; 67(9):677-80. PubMed ID: 25095805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia.
    Lee CH; Tang YF; Su LH; Chien CC; Liu JW
    Microb Drug Resist; 2008 Sep; 14(3):233-7. PubMed ID: 18707240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
    Fan B; Guan J; Wang X; Cong Y
    PLoS One; 2016; 11(6):e0157757. PubMed ID: 27315107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.
    Peck KR; Kim MJ; Choi JY; Kim HS; Kang CI; Cho YK; Park DW; Lee HJ; Lee MS; Ko KS
    J Med Microbiol; 2012 Mar; 61(Pt 3):353-360. PubMed ID: 22016557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli.
    Wang Y; Li H; Xie X; Wu X; Li X; Zhao Z; Luo S; Wan Z; Liu J; Fu L; Li X
    J Glob Antimicrob Resist; 2020 Mar; 20():351-359. PubMed ID: 31557565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of Colistin-Ampicillin/Sulbactam Combination Efficacy in Imipenem-Resistant Acinetobacter baumannii Strains].
    Cıkman A; Ceylan MR; Parlak M; Karahocagil MK; Berktaş M
    Mikrobiyol Bul; 2013 Jan; 47(1):147-51. PubMed ID: 23390912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P; Amornnopparattanakul S; Panapakdee S; Fungwithaya S; Nannha P; Dhiraputra C; Leelarasamee A
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
    J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
    Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.
    Wolff M; Joly-Guillou ML; Farinotti R; Carbon C
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1406-11. PubMed ID: 10348761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.